Kalos Management, Inc. Abb Vie Inc. Transaction History

Kalos Management, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 05, 2023	BUY	$144.61 - $166.54 $23,860 - $27,479	165 New	165 $26,000
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $89,728 - $114,073	-652 Reduced 13.1%	4,325 $664,000
Q1 2022 Jun 21, 2022	SELL	$131.98 - $163.75 $1.71 Million - $2.12 Million	-12,938 Reduced 72.22%	4,977 $806,000
Q4 2021 Feb 03, 2022	BUY	$107.43 - $135.93 $55,971 - $70,819	521 Added 3.0%	17,915 $2.07 Million
Q3 2021 Nov 10, 2021	BUY	$106.4 - $120.78 $1.56 Million - $1.77 Million	14,622 Added 527.49%	17,394 $2.01 Million
Q2 2021 Aug 11, 2021	SELL	$105.21 - $117.21 $12,309 - $13,713	-117 Reduced 4.05%	2,772 $315,000
Q1 2021 May 13, 2021	SELL	$102.3 - $112.62 $36,623 - $40,317	-358 Reduced 11.03%	2,889 $327,000
Q4 2020 Feb 11, 2021	BUY	$80.49 - $108.67 $7,888 - $10,649	98 Added 3.11%	3,247 $344,000
Q3 2020 Nov 12, 2020	BUY	$85.91 - $100.83 $11,769 - $13,813	137 Added 4.55%	3,149 $297,000
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $220,990 - $295,718	3,012 New	3,012 $288,000
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $733,687 - $982,476	-7,974 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $57,049 - $62,559	637 Added 8.68%	7,974 $778,000
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $20,046 - $25,606	287 Added 4.07%	7,337 $652,000
Q2 2017 Aug 15, 2017	BUY	N/A	7,050	7,050 $511,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Kalos Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kalos Management, Inc. with notifications on news.